SpaceX Mobile Network Could Cost Up to $130 Billion, Bernstein Says 
Asian Currencies Rise as Yen Surges on Fed Rate Outlook 
Treasury Yields Set to Stay High as Debt Supply Pressures Bond Market 
OpenAI Launches GPT-6 Astra With Advanced AI Agent Capabilities 
Bank of England Sees Surge in Higher-Risk Collateral 
Asian Currencies Weaken as Dollar Rises, Kiwi Slides After RBNZ Hike 
Oil Prices Rise as US-Iran Conflict Threatens Middle East Supply 
Chinese AI Stocks Rally After OpenAI Launches GPT-6 Astra 
Australia GDP Beats Forecast, Boosting RBA Rate Hike Bets 
ByteDance Secures $29.6 Billion Loan to Boost AI Investment 
Microsoft to Reveal Azure Revenue in Major Reporting Shake-Up 
Deutsche Telekom Shares Rise as Elliott Pushes Against T-Mobile Merger 
Pinterest Stock Falls as CFO Julia Brau Donnelly Resigns 
South Korea Inflation Rises to 3.1% in August 
MongoDB Stock Sinks 14% as Atlas Growth Misses Expectations 
FTSE 100 Falls as US-Iran Conflict Drives Oil Prices Higher 
Add as a preferred source on Google
Samsung C&T attributed its first-quarter net profit surge of 55.8 percent to equity gains from its affiliate Samsung Biologics and profitable overseas projects.
The company, a construction affiliate of the Samsung Group, said in a regulatory filing that it had a net profit of 346.5 billion won for January to March, up from 222.4 billion won in the same period a year before.
Samsung C&T owns a 43.3 percent share in Samsung Biologics, a biopharmaceutical unit of Samsung Group.
The company claimed a first-quarter increase of 39.8 percent in its operating profit to 147 billion from 105 billion won in the same period last year.
However, Samsung C&T's revenue of 6.96 trillion won is a 5.4 percent dip from 7.35 trillion won last year. It attributed the drop to decreasing domestic consumption, and trading volume brought about by the COVID-19 situation, and for the completion of construction projects undertaken by the company.
Shares in Samsung C&T is up 3.3 percent to 97,000 won, outperforming KOSPI's gain of 0.89 percent gain.
"Increased equity gains from Samsung Biologics and profitable overseas projects boosted the first-quarter net profit," an official of Samsung C&T said.
